Goldline Pharmaceutical Stock: price and insider trades · India

Every trade that managers of Goldline Pharmaceutical disclose to SEBI (PIT + SAST) is tracked on this page. 3 insiders have disclosed 6 filings since 18 October 2025.

Not one open-market sale was filed. On the buying side, 3 insiders reported 6 purchases totalling €24k. No amount is published for 3 filings, which the totals therefore leave out. Unlike grants, an open-market purchase is paid for by the insider, at the market price. At €24k, the purchase published on 23 June 2026 by Swapan Khandelwal is the largest of the period. The buyers include 3 senior executives.

For context, the typical company on the same exchange (median of 1,984 companies) published 4 filings over the same period, against 6 filings here. Since 2026, the database holds 6 purchases and no sales by insiders of the company.

The data flag 1 purchase as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The clock since the last published purchase (1 September 2026) now reads 47 days. Most trades are made public on the day they happen. That lag is the time during which only the insider knows about the trade.

This summary is built from SEBI (PIT + SAST) disclosures alone and does not predict where the share price will go.